Novartis
☆ WatchFor more than 250 years–and 30 years as Novartis–we’ve pursued scientific breakthroughs for one purpose: people. Today, we take on the toughest challenges in healthcare and turn innovations into medic observed
fresh
For more than 250 years–and 30 years as Novartis–we’ve pursued scientific breakthroughs for one purpose: people. Today, we take on the toughest challenges in healthcare and turn innovations into medic observed
No person- or entity-level identity check is on record for this company. A name match is not one.
The inclusion bar: two or more independent sourced evidence families. This profile is reachable but not in the ranked index. It is a statement about how much evidence we hold, and about nothing else.
We have not established fit. That is not a soft no and not a soft yes — it is unknown, and it is never counted as a qualified prospect.
No standout signal or flag yet.
No single number decides. Layers can disagree — that's the point. New to this? →
we have great partnerships with Eli Lilly. I think you had the CEO speaking earlier, and Novartis, which are fantastic, and our own internal drug programs.
I think you're going to see two things, which is the sort of democratization of these tools for everybody to just use and create with without having to learn incredibly complex UXs and UIs like we had to do in the past. But on the other hand, I think we're also collaborating with filmmakers and top creators and artists. So, they're helping us design what these new tools should be. What features would they want? People like the director, Darren Aronofsky, who's a good friend of mine, an amazing d
with Nano Banana, what's amazing about it is that it's an image generator. It's state-of-the-art and best-in-class.
No, I mean, we're not seeing that internally. And we're still seeing a huge rate of progress.
So I think that we are maybe, you know, I would say sort of five to 10 years away from having an AGI system that's capable of doing those things.
Gray-market attention, not quality. 3+ HN mentions (peak 4 points). Claim-shaped headlines are rumors until corroborated — a Tier-3 factual claim carries no evidentiary weight on its own. ▲ 4 Novartis to donate 130M doses of hydroxychloroquine to fight coronavirus 2020-03-24 ↗
| Attribute | Value | Kind | Source | Observed | State | Conf. |
|---|---|---|---|---|---|---|
common_name | Novartis | observed | artifact ↗ | 2026-07-18 | normalized | 0.60 |
common_name | Novartis | observed | artifact ↗ | 2026-07-24 | normalized | 0.60 |
community.hn.max_points | 254 | observed | artifact ↗ | 2026-07-18 | superseded | 0.20 |
community.hn.max_points | 4 | observed | artifact ↗ | 2026-10-08 | normalized | 0.20 |
community.hn.mentions | 50 | observed | artifact ↗ | 2026-07-18 | superseded | 0.20 |
community.hn.mentions | 3 | observed | artifact ↗ | 2026-10-08 | normalized | 0.20 |
community.hn.rumors | [{"url": "https://news.ycombinator.com/item?id=45715987", "title": "Novartis to acquire Avidity Biosciences for $12B", "points": 3, "created_at": "2025-10-26", "evidence_type": "rumor", "verification_ | observed | artifact ↗ | 2026-07-18 | superseded | 0.20 |
community.hn.rumors | [{"url": "https://news.ycombinator.com/item?id=45715987", "title": "Novartis to acquire Avidity Biosciences for $12B", "points": 3, "created_at": "2025-10-26", "evidence_type": "rumor", "verification_ | observed | artifact ↗ | 2026-08-16 | superseded | 0.20 |
community.hn.rumors | [{"url": "https://news.ycombinator.com/item?id=45715987", "title": "Novartis to acquire Avidity Biosciences for $12B", "points": 3, "created_at": "2025-10-26", "evidence_type": "rumor", "verification_ | observed | artifact ↗ | 2025-10-26 | superseded | 0.20 |
community.hn.rumors | [{"url": "https://news.ycombinator.com/item?id=45715987", "title": "Novartis to acquire Avidity Biosciences for $12B", "points": 3, "created_at": "2025-10-26", "evidence_type": "rumor", "verification_ | observed | artifact ↗ | 2025-10-26 | superseded | 0.20 |
community.hn.rumors | [{"url": "https://news.ycombinator.com/item?id=45715987", "title": "Novartis to acquire Avidity Biosciences for $12B", "points": 3, "created_at": "2025-10-26", "evidence_type": "rumor", "verification_ | observed | artifact ↗ | 2025-10-26 | superseded | 0.20 |
community.hn.rumors | [{"url": "https://news.ycombinator.com/item?id=45715987", "title": "Novartis to acquire Avidity Biosciences for $12B", "points": 3, "created_at": "2025-10-26", "evidence_type": "rumor", "verification_ | observed | artifact ↗ | 2025-10-26 | superseded | 0.20 |
community.hn.rumors | [{"url": "https://news.ycombinator.com/item?id=45715987", "title": "Novartis to acquire Avidity Biosciences for $12B", "points": 3, "created_at": "2025-10-26", "evidence_type": "rumor", "verification_ | observed | artifact ↗ | 2025-10-26 | superseded | 0.20 |
community.hn.rumors | [{"url": "https://news.ycombinator.com/item?id=45715987", "title": "Novartis to acquire Avidity Biosciences for $12B", "points": 3, "created_at": "2025-10-26", "evidence_type": "rumor", "verification_ | observed | artifact ↗ | 2025-10-26 | superseded | 0.20 |
community.hn.rumors | [] | observed | artifact ↗ | 2026-10-08 | normalized | 0.20 |
community.hn.top_story | {"url": "https://news.ycombinator.com/item?id=5472087", "title": "India Supreme Court rejects Novartis' right to patent new version of cancer drug", "points": 254, "created_at": "2013-04-01"} | observed | artifact ↗ | 2026-07-18 | superseded | 0.20 |
community.hn.top_story | {"url": "https://news.ycombinator.com/item?id=5472087", "title": "India Supreme Court rejects Novartis' right to patent new version of cancer drug", "points": 254, "created_at": "2013-04-01"} | observed | artifact ↗ | 2026-08-16 | superseded | 0.20 |
community.hn.top_story | {"url": "https://news.ycombinator.com/item?id=5472087", "title": "India Supreme Court rejects Novartis' right to patent new version of cancer drug", "points": 254, "created_at": "2013-04-01"} | observed | artifact ↗ | 2013-04-01 | superseded | 0.20 |
community.hn.top_story | {"url": "https://news.ycombinator.com/item?id=5472087", "title": "India Supreme Court rejects Novartis' right to patent new version of cancer drug", "points": 254, "created_at": "2013-04-01"} | observed | artifact ↗ | 2013-04-01 | superseded | 0.20 |
community.hn.top_story | {"url": "https://news.ycombinator.com/item?id=5472087", "title": "India Supreme Court rejects Novartis' right to patent new version of cancer drug", "points": 254, "created_at": "2013-04-01"} | observed | artifact ↗ | 2013-04-01 | superseded | 0.20 |
community.hn.top_story | {"url": "https://news.ycombinator.com/item?id=5472087", "title": "India Supreme Court rejects Novartis' right to patent new version of cancer drug", "points": 254, "created_at": "2013-04-01"} | observed | artifact ↗ | 2013-04-01 | superseded | 0.20 |
community.hn.top_story | {"url": "https://news.ycombinator.com/item?id=5472087", "title": "India Supreme Court rejects Novartis' right to patent new version of cancer drug", "points": 254, "created_at": "2013-04-01"} | observed | artifact ↗ | 2013-04-01 | superseded | 0.20 |
community.hn.top_story | {"url": "https://news.ycombinator.com/item?id=5472087", "title": "India Supreme Court rejects Novartis' right to patent new version of cancer drug", "points": 254, "created_at": "2013-04-01"} | observed | artifact ↗ | 2013-04-01 | superseded | 0.20 |
community.hn.top_story | {"url": "https://news.ycombinator.com/item?id=22670516", "title": "Novartis to donate 130M doses of hydroxychloroquine to fight coronavirus", "points": 4, "created_at": "2020-03-24"} | observed | artifact ↗ | 2020-03-24 | superseded | 0.20 |
community.hn.top_story | {"url": "https://news.ycombinator.com/item?id=22670516", "title": "Novartis to donate 130M doses of hydroxychloroquine to fight coronavirus", "points": 4, "created_at": "2020-03-24"} | observed | artifact ↗ | 2020-03-24 | normalized | 0.20 |
description | A company interested in radiotherapies, part of the 15 billion M&A and deal making in the last few years. | observed | artifact ↗ | 2026-07-18 | normalized | 0.60 |
description | For more than 250 years–and 30 years as Novartis–we’ve pursued scientific breakthroughs for one purpose: people. Today, we take on the toughest challenges in healthcare and turn innovations into medic | observed | artifact ↗ | 2026-07-24 | normalized | 0.70 |
domain | www.novartis.com | observed | artifact ↗ | 2026-07-24 | normalized | 0.95 |
index.ai_tie | NOT_AI | observed | classify | 2026-07-25 | derived | 0.60 |
platform.index_excluded | true | derived | calc | 2026-09-28 | normalized | 0.99 |
sector | biotech | derived | calc | 2026-08-08 | normalized | 0.70 |
signal.commentary | {"context": null, "run_ref": "01KXZS7S0JJR1R9650EFSB52QD", "signals": [{"quote": "So I think that we are maybe, you know, I would say sort of five to 10 years away from having an AGI system that's cap | observed | artifact ↗ | 2025-09-12 | promoted | 0.50 |
signal.commentary | {"context": null, "run_ref": "01KXZS7S0JJR1R9650EFSB52QD", "signals": [{"quote": "No, I mean, we're not seeing that internally. And we're still seeing a huge rate of progress.", "stance": "bullish", " | observed | artifact ↗ | 2025-09-12 | promoted | 0.50 |
signal.commentary | {"context": null, "run_ref": "01KXZS7S0JJR1R9650EFSB52QD", "signals": [{"quote": "with Nano Banana, what's amazing about it is that it's an image generator. It's state-of-the-art and best-in-class.", | observed | artifact ↗ | 2025-09-12 | promoted | 0.50 |
signal.commentary | {"context": null, "run_ref": "01KXZS7S0JJR1R9650EFSB52QD", "signals": [{"quote": "I think you're going to see two things, which is the sort of democratization of these tools for everybody to just use | observed | artifact ↗ | 2025-09-12 | promoted | 0.50 |
signal.commentary | {"context": null, "run_ref": "01KXZS7S0JJR1R9650EFSB52QD", "signals": [{"quote": "we have great partnerships with Eli Lilly. I think you had the CEO speaking earlier, and Novartis, which are fantastic | observed | artifact ↗ | 2025-09-12 | promoted | 0.50 |
source.document.reference | {"kind": "video", "title": "All-In — Best Ideas Pitch Competition — novartis", "source_id": "01KXRPBDZ2FE2BHN1CAREA46SJ-m-9328b082a7756ed3", "extract_ref": "artifact:sha256:d620f51be2974e329f6969a697d | observed | artifact ↗ | 2026-07-18 | normalized | 0.95 |
source.document.reference | {"kind": "video", "title": "Inside Google DeepMind: AGI, Robotics, & World Models Explained - Demis Hassabis — novartis", "source_id": "01KXRSFYGGNABECW5J4Y8P0QZF-m-9328b082a7756ed3", "extract_ref": " | observed | artifact ↗ | 2026-07-20 | normalized | 0.95 |
website_url | https://www.novartis.com | observed | enrichment | 2026-07-24 | normalized | 0.75 |
website_url | https://www.novartis.com | observed | artifact ↗ | 2026-07-24 | normalized | 0.95 |
website.homepage.has_pricing_link | false | observed | artifact ↗ | 2026-07-24 | normalized | 0.80 |